A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine
A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.
| Errataetall: |
UpdateIn: Vaccines (Basel). 2020 Dec 17;8(4):. - PMID 33348607 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
bioRxiv : the preprint server for biology - (2020) vom: 31. Juli |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Weina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 29.12.2020 published: Electronic UpdateIn: Vaccines (Basel). 2020 Dec 17;8(4):. - PMID 33348607 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.07.30.229120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31341615X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31341615X | ||
| 003 | DE-627 | ||
| 005 | 20231225150526.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.07.30.229120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM31341615X | ||
| 035 | |a (NLM)32766572 | ||
| 035 | |a (PII)2020.07.30.229120 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Weina |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 29.12.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Vaccines (Basel). 2020 Dec 17;8(4):. - PMID 33348607 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a McCroskery, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Wen-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Leist, Sarah R |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yonghong |e verfasserin |4 aut | |
| 700 | 1 | |a Albrecht, Randy A |e verfasserin |4 aut | |
| 700 | 1 | |a Slamanig, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Oliva, Justine |e verfasserin |4 aut | |
| 700 | 1 | |a Amanat, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Schaefer, Alexandra |e verfasserin |4 aut | |
| 700 | 1 | |a Dinnon, Kenneth H |e verfasserin |4 aut | |
| 700 | 1 | |a Innis, Bruce L |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Sastre, Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Baric, Ralph S |e verfasserin |4 aut | |
| 700 | 1 | |a Palese, Peter |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv : the preprint server for biology |d 2020 |g (2020) vom: 31. Juli |w (DE-627)NLM31090014X |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:31 |g month:07 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.07.30.229120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 31 |c 07 | ||